Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Advanced solid tumor
Clinical practice guideline
Neurotrophic receptor tyrosine kinase (NTRK) fusion
Tropomyosin receptor kinase (TRK) inhibitor
Tumor-agnostic treatment
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
13
12
2019
accepted:
20
12
2019
pubmed:
25
1
2020
medline:
12
6
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy of tropomyosin receptor kinase inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors have been established as the second tumor-agnostic treatment, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with NTRK-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and Japanese Society of Pediatric Hematology/Oncology, and the public comments among all Societies' members was done. The current guideline describes 3 clinical questions and 15 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. In the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.
Sections du résumé
BACKGROUND
BACKGROUND
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy of tropomyosin receptor kinase inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors have been established as the second tumor-agnostic treatment, making it necessary to develop the guideline prioritized for these patients.
METHODS
METHODS
Clinical questions regarding medical care were formulated for patients with NTRK-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and Japanese Society of Pediatric Hematology/Oncology, and the public comments among all Societies' members was done.
RESULTS
RESULTS
The current guideline describes 3 clinical questions and 15 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors.
CONCLUSION
CONCLUSIONS
In the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.
Identifiants
pubmed: 31974683
doi: 10.1007/s10147-019-01610-y
pii: 10.1007/s10147-019-01610-y
pmc: PMC7046581
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Receptor, trkA
EC 2.7.10.1
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-417Subventions
Organisme : Japanese Society of Medical Oncology
ID : N/A
Organisme : Japan Society of Clinical Oncology
ID : N/A
Organisme : Ministry of Health, Labour and Welfare
ID : H29 -measures against cancers- public-013
Références
Hum Pathol. 2013 Oct;44(10):1982-8
pubmed: 23773480
Nat Genet. 1998 Feb;18(2):184-7
pubmed: 9462753
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Future Oncol. 2005 Oct;1(5):689-98
pubmed: 16556046
J Transl Med. 2016 Dec 14;14(1):339
pubmed: 27974047
Cancer Cell. 2002 Nov;2(5):367-76
pubmed: 12450792
J Thorac Oncol. 2018 Oct;13(10):1474-1482
pubmed: 29935306
JCO Precis Oncol. 2018;2018:
pubmed: 30637364
Nat Commun. 2014 Sep 10;5:4846
pubmed: 25204415
Mod Pathol. 2020 Jan;33(1):38-46
pubmed: 31375766
Am J Surg Pathol. 2000 Jul;24(7):937-46
pubmed: 10895816
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
J Pathol. 2016 Mar;238(4):543-9
pubmed: 26606880
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Cell. 1991 Apr 5;65(1):189-97
pubmed: 1849459
JCO Precis Oncol. 2018;2018:
pubmed: 30215037
J Clin Pathol. 2019 Jul;72(7):460-467
pubmed: 31072837
Cancer Res. 2019 Jul 1;79(13):3163-3168
pubmed: 31196931
N Engl J Med. 1993 Mar 25;328(12):847-54
pubmed: 8441429
Eur J Cancer. 2016 Apr;57:1-9
pubmed: 26849118
Int J Clin Oncol. 2020 Feb;25(2):217-239
pubmed: 31286289
Nature. 1982 Dec 9;300(5892):539-42
pubmed: 7144906
Genes Chromosomes Cancer. 2004 Jun;40(2):152-7
pubmed: 15101049
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Laryngoscope. 2014 Jan;124(1):188-195
pubmed: 23775296
Am J Surg Pathol. 2017 Nov;41(11):1547-1551
pubmed: 28719467
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):513-523
pubmed: 27028240
Am J Surg Pathol. 2015 Nov;39(11):1458-67
pubmed: 26291510
ESMO Open. 2016 Mar 18;1(2):e000023
pubmed: 27843590
Am J Surg Pathol. 2010 May;34(5):599-608
pubmed: 20410810
Cancer Discov. 2015 Jan;5(1):25-34
pubmed: 25527197
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Am J Pathol. 1998 Nov;153(5):1451-8
pubmed: 9811336
Am J Surg Pathol. 2016 Jan;40(1):3-13
pubmed: 26492182
Science. 1991 Apr 26;252(5005):554-8
pubmed: 1850549
Mol Cell Biol. 2000 Dec;20(23):8655-66
pubmed: 11073967